Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Delstrigo · 1 trial · 1 indication
HIV1-RNA
| Arm | Type | Description |
|---|---|---|
| Treatment Group 1 | EXPERIMENTAL | Delstrigo |
| Treatment Group 2 | OTHER | KOCITAF |
| Name | Type | Description |
|---|---|---|
| Delstrigo | DRUG | Treatment Group 1 Participants will receive Doravirine, as part of a fixed-dose oral combination with lamivudine and tenofovir disoproxil fumarate (DOR/3TC/TDF, Delstrigo)tablets which are to be administered orally and once daily. |
| KOCITAF | DRUG | Treatment Group 2 Participants will receive dolutegravir, as part of a fixed-dose oral combination with tenofovir alafenamide plus emtricitabine (DTG/TAF/FTC, KOCITAF) tablets which are to be administered orally and once daily. |
Inclusion Criteria: Each participant must meet all the following criteria to be enrolled in this study. * ≥18 years old, male or female. * Documented laboratory diagnosis of infection with HIV-1 (positive enzyme-linked immunosorbent assay HIV-1 antibody test) at screening, with no baseline DOR res...
Top 20 of 28 competitors
Delstrigo is an investigational small molecule being developed for the treatment of HIV-1 infection. It is currently in Phase 3 clinical development as a first-line antiretroviral therapy for adults with HIV-1.
Delstrigo is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker symbol MRK. The company is conducting a Phase 3 clinical trial of the drug in South Africa.
Delstrigo is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 non-inferiority study is currently active but not recruiting participants.
Delstrigo is being studied in a Phase 3 clinical trial with the identifier NCT05924438. This randomized, controlled study is comparing DOR/3TC/TDF to DTG/TAF/FTC in participants with HIV-1 starting first-line antiretroviral therapy. The trial is enrolling 600 participants in South Africa.
Delstrigo is a combination of the drugs doravirine, lamivudine, and tenofovir disoproxil fumarate, which is abbreviated as DOR/3TC/TDF. In the Phase 3 clinical trial, this combination is being compared to another regimen, DTG/TAF/FTC.